Vol 45, No 4 (2014)
Prace poglądowe / Reviews
Published online: 2014-10-01

open access

Page views 152
Article views/downloads 483
Get Citation

Connect on Social Media

Connect on Social Media

Treatment of high-risk myelodysplastic syndromes in adults according to European LeukemiaNet recommendations

Agnieszka Wierzbowska, Agnieszka Pluta1
DOI: 10.1016/j.achaem.2014.11.002
Acta Haematol Pol 2014;45(4):313-321.


High-risk myelodysplastic syndromes (MDS) are defined by patients who fall into Intermediate-2 or High-risk group categories in the International Prognostic Scoring System or High/Very high in the revised IPSS (R-IPSS). High-risk MDS carry a major risk of progression to acute myeloid leukemia and short survival. Standard therapies include allogeneic stem cell transplantation, induction therapy (AML-like) and hypomethylating agents. This article presents recent European LeukemiaNet recommendations for treatment of high-risk MDS.

Article available in PDF format

View PDF (Polish) Download PDF file